An FDA field investigator who arrives at a 503A compounding pharmacy does not wait for records to be located. The inspection moves at the pace of what the pharmacy can produce on the spot, and the difference between a routine closeout and an FDA Form 483 observation can turn on whether the documentation is already assembled before anyone asks for it. FDA's compounding inspections focus first on whether every preparation traces back to a valid, patient-specific prescription, then move to the distribution, complaint, and supplier records that establish the pharmacy's footing under Section 503A of the Federal Food, Drug, and Cosmetic Act. A pharmacy that cannot produce these records promptly gives the investigator reason to look further.
Prescription and Formulation Records
Section 503A exempts pharmacy compounding from FDA's drug approval and current good manufacturing practice (cGMP) requirements only when the preparation is made for an individually identified patient under a valid prescription, or within the anticipatory-compounding allowance tied to a documented, patient-specific prescribing history. The pharmacy should be able to produce, for any compounded preparation named in an inspection, the prescription itself, the patient-specific documentation supporting it, and the master formulation record and compounding record showing the ingredients, quantities, and the beyond-use date assigned to that batch. Where a preparation falls under the anticipatory exception rather than a prescription on hand, the file should show the basis for that determination, not just the finished label.
Distribution, Complaint, and Supplier Records
Three other record sets matter just as much: distribution and shipping records, complaint and adverse event files, and supplier qualification records. Distribution and shipping records show where each compounded preparation went, which matters because Section 503A also limits how a pharmacy's out-of-state distribution is treated before additional requirements apply. Complaint and adverse event files show whether the pharmacy has a system for logging, investigating, and, where warranted, reporting a complaint about a compounded preparation. Supplier qualification records, including the certificate of analysis required for each bulk drug substance, show that the pharmacy verified the identity, strength, and quality of what went into the preparation before it was compounded.
Monitoring, Certification, and Training Documentation
A separate set of records, covering environmental and personnel monitoring, cleanroom certification, sterility and endotoxin testing, and staff training, documents the pharmacy's sterile and hazardous compounding program under USP 797/800. These records are organized and retained as part of that compliance program rather than assembled specifically for an FDA visit, and they should be retrievable the same way: by preparation type and by date, with the person who can produce each file identified in advance.
The Scope of FDA's Access to Pharmacy Records
The Federal Food, Drug, and Cosmetic Act gives FDA broad access to records, files, and papers at a drug manufacturing establishment. 21 U.S.C. § 374(a)(2)(A) treats a pharmacy differently when it meets the statute's conditions: operating under state pharmacy law, dispensing on valid prescriptions, and compounding only in the regular course of retail dispensing. For a pharmacy that qualifies, the inspection authority the statute allows is narrower than the full records-and-files access that applies to a manufacturer. Whether a given pharmacy's compounding stays within the regular course of retail dispensing, and so keeps that narrower scope, is a fact-specific determination, and it is best worked out with counsel before an investigator is on site.
The records a 503A pharmacy can produce on the day of an inspection say as much about its compliance program as the preparations themselves.
Why Early Legal Counsel Is Critical
It is critical that a compounding pharmacy promptly retain experienced healthcare defense counsel upon receiving notice of an FDA inspection, a Form 483, or a warning letter. Early legal involvement can help protect the pharmacy's rights, support an organized and accurate response to the agency's requests, help avoid inadvertent admissions, and allow counsel to communicate with FDA on the pharmacy's behalf. Delaying legal representation can affect the outcome of the inspection and expose the pharmacy to risk that organized records and informed counsel could have reduced.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients nationwide.
The firm's compounding pharmacy practice works with 503A pharmacies before, during, and after an FDA inspection, organizing the records above into a retrievable set, reviewing formulation and distribution practices against Section 503A's conditions, and responding once a Form 483 or warning letter is issued. Contact Health Law Alliance's compounding pharmacy attorneys for a free, confidential consultation.
